In this November news roundup we highlight some of the top stories of the month, including several FDA approvals, new breast cancer guidelines, and more.
Forming International Collaborative Efforts to Assess Metformin Use in LFS
Investigators from the United States, United Kingdom, Canada, and Germany look to conduct a primary prevention trial in patients with Li-Fraumeni syndrome.
Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic Diseases
A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.
City of Hope Claims Victory After Updated CROWN Presentation Data in NSCLC
Experts in non–small cell lung cancer met to debate the latest advances and treatment options and the hottest topics in the space.
Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma
Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.
FDA Accepts NDA Resubmission of Rivoceranib/Camrelizumab in uHCC
The resubmission included an analysis of the phase 3 CARES-310 study, which reported favorable overall survival with the combination therapy in uHCC.
Expert Commentary on the Product Profile of Lazertinib in NSCLC
Jenan Dailey, PharmD, BCAP, spoke about the approval of lazertinib plus amivantamab as first-line treatment for patients with locally advanced or metastatic NSCLC.